drugset / Trial / NCT07260708
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
Phase 1
Recruiting
42 enrolled
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I clinical study aimed at evaluating the safety and pharmacokinetics of TQB2922 subcutaneous injection in patients with advanced cancers.
Timeline
- Start
- 2025-12-16
- Primary completion
- 2028-12
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2922 | Unknown | — | Subcutaneous |